Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 83
- Registration Number
- NCT00825734
- Locations
- ๐บ๐ธ
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
๐บ๐ธFlorida Cancer Specialists, Ft. Myers, Florida, United States
๐บ๐ธSt. Louis Cancer Care, Chesterfield, Missouri, United States
Study of Sorafenib/Cetuximab in Head and Neck Cancer
- First Posted Date
- 2008-12-30
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Duke University
- Target Recruit Count
- 31
- Registration Number
- NCT00815295
- Locations
- ๐บ๐ธ
Duke University Health System, Durham, North Carolina, United States
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00813293
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- Drug: RG1507Drug: RO1507Drug: erlotinib [Tarceva]Drug: bevacizumab [Avastin]Drug: pemetrexelDrug: carboplatinDrug: capecitabine [Xeloda]Drug: sorafenibDrug: temozolomideDrug: cetuximabDrug: paclitaxelDrug: etoposideDrug: mFOLFOX6Drug: trastuzumab [Herceptin]Drug: docetaxelDrug: gemcitabineDrug: irinotecan
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT00811993
Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 50
- Registration Number
- NCT00810394
- Locations
- ๐บ๐ธ
University of California Davis Cancer Center, Sacramento, California, United States
Sorafenib in Previously Treated Malignant Mesothelioma
- Conditions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2009-08-04
- Lead Sponsor
- King's College London
- Target Recruit Count
- 54
- Registration Number
- NCT00794859
- Locations
- ๐ฌ๐ง
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT00791544
- Locations
- ๐ซ๐ท
Sanofi-Aventis Administrative Office, Paris, France
Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2012-11-29
- Target Recruit Count
- 12
- Registration Number
- NCT00789763
- Locations
- ๐ช๐ธ
Hospital Universitario La Paz, Madrid, Spain
๐ช๐ธHospital de La Santa Creu I Sant Pau, Barcelona, Spain
๐ช๐ธHospital Clinic I Provincial, Barcelona, Spain
Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 30
- Registration Number
- NCT00786110
- Locations
- ๐ฎ๐น
Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
๐ฎ๐นAzienda Ospedaliera di Padova, Padova, Italy
๐ฎ๐นIst. Clin.Humanitas, Rozzano, Italy
RDEA119 and Sorafenib Combination Dose Escalation Study
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT00785226
- Locations
- ๐บ๐ธ
UPenn, Philadelphia, Pennsylvania, United States
๐จ๐ฆToronto General Hospital, Toronto, Ontario, Canada
๐บ๐ธUSC/Norris Comprehensive Cancer Center and LAC/USC Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.